Real-life Evaluation of WEGOVY (Semaglutide) Treatment in Adults With Monogenic Obesity (ObGeSema)

Imagine your body's system for controlling hunger and weight, like a set of scales. For some people, a mix of things like diet and activity can tip these scales. But for others, there's a specific genetic change, like a tiny instruction mistake in their body's blueprint, that stops these scales from working properly. This is called monogenic obesity, and it's a rare type that often starts when someone is still a child or teenager.

People with monogenic obesity can find it very hard to manage their weight, even with careful diet plans and exercise. Sometimes, even weight-loss surgery doesn't provide long-lasting benefits for them. This can have a big impact on their health and daily lives. Because of this, doctors are actively searching for new and more effective ways to help.

Recently, a new medication called Wegovy (semaglutide) has become available and has shown good results for people with more common types of obesity. This study wants to see if Wegovy can also be a helpful treatment for adults with monogenic obesity. Researchers want to collect information from people already using or about to start Wegovy to understand if it works similarly for this specific genetic condition, offering a new hope for better weight management and health.